Table 3.
List of carnitine and acylcarnitines detected in both cohorts.
| Compound | Comparative Analysis | |||
|---|---|---|---|---|
| Parkinson’s disease/Control | ||||
| 1st cohort | 2nd cohort | |||
| Ratio | P-valuea | Ratio | P-valuea | |
| Creatinine | 1.08 | 0.0876 | 0.894 | 0.0073 |
| Creatine | 1.01 | 0.758 | 0.943 | 0.143 |
| 3-Methylhistidine | 0.991 | 0.718 | 0.998 | 0.816 |
| Carnitine | 1.02 | 0.635 | 0.949 | 0.0491 |
| AC(2:0) | 1.04 | 0.444 | 0.94 | 0.198 |
| AC(4:0), Isobutyrylcarnitine | 1.25 | 0.0354 | 0.934 | 0.109 |
| AC(4:0), Butyrylcarnitine | — | — | 1.15 | 0.235 |
| AC(8:0) | 1.09 | 0.645 | 0.956 | 0.312 |
| AC(12:0) | 0.505 | <0.0001 | 0.675 | 0.0146 |
| AC(12:1) | 0.546 | <0.0001 | — | — |
| AC(12:1)-1 | — | — | 0.762 | 0.0176 |
| AC(12:1)-2 | — | — | 0.632 | 0.0002 |
| AC(13:1) | 0.608 | <0.0001 | — | — |
| AC(14:0) | 0.532 | <0.0001 | 0.766 | 0.0252 |
| AC(14:1) | 0.662 | 0.0043 | 0.72 | 0.0173 |
| AC(14:2) | 0.628 | <0.0001 | 0.735 | 0.0187 |
| AC(14:3) | 0.86 | 0.0415 | — | — |
| AC(15:0) | 1.02 | 0.449 | — | — |
| AC(15:0)-1 | — | — | 0.292 | <0.0001 |
| AC(15:0)-2 | — | — | 0.235 | <0.0001 |
| AC(16:0) | 0.543 | <0.0001 | 0.767 | 0.0205 |
| AC(16:1) | 0.582 | <0.0001 | 0.824 | 0.0421 |
| AC(16:2) | 0.716 | 0.0006 | — | — |
| AC(18:0) | 0.599 | <0.0001 | 0.82 | 0.0734 |
| AC(18:1) | 0.566 | <0.0001 | 0.803 | 0.0739 |
| AC(18:2) | 0.588 | <0.0001 | — | — |
| AC(20:1) | 0.697 | 0.0007 | 0.952 | 0.664 |
Abbreviations: AC = acylcarnitine.
a P-value obtained by Wilcoxon’s test, comparing between PD and controls.